Unknown

Dataset Information

0

Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.


ABSTRACT: The widely employed anti-diabetic drug pioglitazone (Actos) is shown to be a specific and reversible inhibitor of human monoamine oxidase B (MAO B). The crystal structure of the enzyme-inhibitor complex shows the R-enantiomer is bound with the thiazolidinedione ring near the flavin. The molecule occupies both substrate and entrance cavities of the active site establishing non-covalent interactions with the surrounding amino acids. These binding properties differentiate pioglitazone from the clinically used MAO inhibitors, which act through covalent inhibition mechanisms and do not exhibit a high degree of MAO A versus B selectivity. Rosiglitazone (Avandia) and troglitazone, other members of the glitazone class, are less selective in that they are weaker inhibitors of both MAO A and MAO B These results suggest that pioglitazone may have utility as a "re-purposed" neuro-protectant drug in retarding the progression of disease in Parkinson's patients. They also provide new insights for the development of reversible isoenzyme-specific MAO inhibitors.

SUBMITTER: Binda C 

PROVIDER: S-EPMC3263826 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC187837 | biostudies-literature
| S-EPMC6442233 | biostudies-literature
| S-EPMC1949415 | biostudies-literature
| S-EPMC2693004 | biostudies-literature
| S-EPMC2706497 | biostudies-literature
| S-EPMC6152246 | biostudies-literature
| S-EPMC5316268 | biostudies-literature
| S-EPMC3071873 | biostudies-literature
| S-EPMC1173910 | biostudies-other
| S-EPMC5947877 | biostudies-literature